Chinese Journal of Pharmacovigilance ›› 2018, Vol. 15 ›› Issue (6): 372-373.
Previous Articles Next Articles
ZHANG Fan1, WANG Li-xia2
Received:2018-08-03
Revised:2018-08-03
Online:2018-06-15
Published:2018-08-03
CLC Number:
ZHANG Fan, WANG Li-xia. One Case of Transaminase Elevation Induced by Liraglutide Injection[J]. Chinese Journal of Pharmacovigilance, 2018, 15(6): 372-373.
| [1] 李博, 高蕊, 唐旭东, 等. 药物临床试验不良反应/不良事件关联性判定方法研究探讨[J]. 中国新药杂志, 2014, 23(12):1465-1470. [2] 熊佩华, 韩俊霞, 成兴波, 等.2 型糖尿病患者胰高血糖素样肽1水平的变化及其临床意义的研究[J].中国糖尿病杂志, 2013, 21(4) : 306-308. [3] 张存志, 邸力强, 曹瑞芳, 等. 利拉鲁肽对治疗欠佳 2 型糖尿病患者疗效观察及安全性研究[J]. 实用糖尿病杂志, 2014, 10(5):15-17. [4] 陈奇盛, 黄翠娟. 二甲双胍联合利拉鲁肽治疗2型糖尿病临床研究[J]. 中外医疗, 2016, 35(35) :121-123. [5] 曲庚汝, 姜莉莉, 吴军. 利拉鲁肽与甘精胰岛素治疗型糖尿病的疗效比较[J]. 中国新药与临床杂志, 2013, 32(9):701-704. [6] 李晓玲, 朱旅云, 单巍, 等. 加用利拉鲁肽治疗单用胰岛素效果不佳的 2 型糖尿病患者的临床观察[J]. 实用糖尿病杂志, 2014, 10(3):33-34. [7] 李骏, 梁金玲, 麦高阳. 百令胶囊联合利拉鲁肽治疗早期糖尿病肾病的疗效观察[J]. 现代药物与临床, 2016, 31(2):174-177. [8] 曹筱佩, 阳池娇. 人胰高血糖素样肽-1类似物的临床疗效及不良反应[J]. 临床药物治疗杂志, 2013,11(1): 45-48. [9] 陈群峰, 王永祥. 利拉鲁肽临床研究进展[J]. 世界临床药物, 2013, 34(5):312-315. [10] 贾王平, 郭代红, 田小燕, 等. 79家医院1110例药物性肝损害不良反应/事件分析[J]. 中国药物警戒, 2017, 14(8):481-485. [11] 董雅芬, 杨秋娅, 胡滨,等. 盐酸胺碘酮注射液致急性肝肾损伤1例[J]. 中国药物警戒, 2017, 14(8):502-503. [12] 贾晓英,李莎. 跌打生骨颗粒致肝损害 1例[J]. 中国药物警戒, 2017, 14(11):703-704. [13] Flint A, Nazzal K, Jagielski P, et al. Influence of hepatic impairment on pharmacokinetics of the long-acting human GLP-1 analogue Liraglutide[J]. Diabetes, 2007, 56(S1):A-145. |
| [1] | SUN Qiyue, ZHAO Ronghua, GUO Shanshan, BAO Lei, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Multiple pharmacological effects of Lingyang Ganmao Oral Liquid [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 127-131. |
| [2] | ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, TAO Xiali, ZHANG Jingsheng, PANG Bo, XU Yingli, CAO Shan, LI Shuran, GUO Shanshan, WANG Daohan, CUI Xiaolan. Mechanisms of Gegen Tang granules against viral pneumonia in mice based on immune regulation [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 132-136. |
| [3] | BAO Lei, GENG Zihan, LI Shuran, JI Zuen, ZHAO Ronghua, SUN Jing, GUO Shanshan, CUI Xiaolan. The critical role of TRP channels in the progression of viral pneumonia [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 137-140. |
| [4] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
| [5] | LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180. |
| [6] | FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184. |
| [7] | ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189. |
| [8] | WANG Shan, XIE Bo, LIU Huimin, LI Zhihao. Adverse event signals for celecoxib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194. |
| [9] | LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198. |
| [10] | XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203. |
| [11] | GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207. |
| [12] | FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210. |
| [13] | LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong. One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212. |
| [14] | CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218. |
| [15] | ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
